Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium

Stock Information for Heat Biologics Inc.

Loading

Please wait while we load your information from QuoteMedia.